MX2009010559A - Derivados de heteroarilo. - Google Patents

Derivados de heteroarilo.

Info

Publication number
MX2009010559A
MX2009010559A MX2009010559A MX2009010559A MX2009010559A MX 2009010559 A MX2009010559 A MX 2009010559A MX 2009010559 A MX2009010559 A MX 2009010559A MX 2009010559 A MX2009010559 A MX 2009010559A MX 2009010559 A MX2009010559 A MX 2009010559A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
general formula
represents hydrogen
compound
Prior art date
Application number
MX2009010559A
Other languages
English (en)
Inventor
Tatsuya Oyama
Masato Matsuoka
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2009010559A publication Critical patent/MX2009010559A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a un compuesto representado por la fórmula [1] o una sal farmacéuticamente aceptable del mismo. (ver fórmula (1)) En la fórmula [1], cualquiera de X e Y es CH y el otro es oxígeno o azufre; R es hidrógeno, etcétera; Z es hidrógeno, etcétera; Ar es fenilo, etcétera; y n es 1 o 2 y m es 1 o 2, excluyendo los compuestos donde n y m son ambos 2. También se proporciona una composición farmacéutica que comprende el compuesto o una sal farmacéuticamente aceptable del mismo como un ingrediente activo. La composición es utilizable como un agente para la prevención o tratamiento de la depresión, trastorno de pánico, ansiedad, trastorno obsesivo-compulsivo, dolor crónico, fibromialgia, obesidad, incontinencia urinaria por estrés, vejiga hiperactiva, etcétera.
MX2009010559A 2007-03-30 2008-03-28 Derivados de heteroarilo. MX2009010559A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007094548 2007-03-30
JP2007146039 2007-05-31
PCT/JP2008/056217 WO2008120761A1 (ja) 2007-03-30 2008-03-28 ヘテロアリール誘導体

Publications (1)

Publication Number Publication Date
MX2009010559A true MX2009010559A (es) 2009-10-22

Family

ID=39808341

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010559A MX2009010559A (es) 2007-03-30 2008-03-28 Derivados de heteroarilo.

Country Status (11)

Country Link
US (1) US8217031B2 (es)
EP (1) EP2141168A4 (es)
JP (1) JP5206669B2 (es)
KR (1) KR20090130094A (es)
AU (1) AU2008233587B2 (es)
BR (1) BRPI0809483A2 (es)
CA (1) CA2682377A1 (es)
MX (1) MX2009010559A (es)
MY (1) MY151072A (es)
RU (1) RU2009140095A (es)
WO (1) WO2008120761A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120095048A1 (en) * 2009-02-20 2012-04-19 Region Midt Jylland Allosteric binding compounds
US9309262B2 (en) 2013-03-13 2016-04-12 Abt Holding Company Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof
MX2016002974A (es) 2013-09-09 2016-06-02 Peloton Therapeutics Inc Eteres de arilo y sus usos.
WO2015095048A1 (en) 2013-12-16 2015-06-25 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
WO2016145032A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144825A1 (en) * 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
WO2020148679A1 (en) * 2019-01-17 2020-07-23 ViiV Healthcare UK (No.4) Limited Process for preparing fostemsavir

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2312246A1 (fr) 1975-05-28 1976-12-24 Parcor Derives de la tetrahydro-4,5,6,7 thieno (3,2-c) pyridine, leur procede de preparation et leurs applications
FR2312247A1 (fr) 1975-05-30 1976-12-24 Parcor Derives de la thieno-pyridine, leur procede de preparation et leurs applications
WO2006004931A2 (en) * 2004-06-30 2006-01-12 Athersys, Inc. Substituted azepine derivatives as serotonin receptor modulators
GB0500300D0 (en) 2005-01-07 2005-02-16 Ionix Pharmaceuticals Ltd Chemical compositions

Also Published As

Publication number Publication date
JPWO2008120761A1 (ja) 2010-07-15
CA2682377A1 (en) 2008-10-09
JP5206669B2 (ja) 2013-06-12
RU2009140095A (ru) 2011-05-10
WO2008120761A1 (ja) 2008-10-09
US8217031B2 (en) 2012-07-10
EP2141168A4 (en) 2011-07-20
AU2008233587B2 (en) 2012-05-17
MY151072A (en) 2014-03-31
AU2008233587A1 (en) 2008-10-09
EP2141168A1 (en) 2010-01-06
KR20090130094A (ko) 2009-12-17
BRPI0809483A2 (pt) 2014-09-09
US20100048537A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
MX2009010559A (es) Derivados de heteroarilo.
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
TW200615266A (en) Organic compounds
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
IL173062A0 (en) Substituted 2-aminotetralin for the treatment of depression
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
TW200614983A (en) 5-substituted-2-phenylamino benzamides as MEK inhibitors
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
NZ545506A (en) Therapeutic agents useful for treating pain
WO2008121348A3 (en) Peripheral opioid receptor antagonists and uses thereof
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
TW200806300A (en) New therapeutic combinations for the treatment of depression
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
TW200637552A (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
MXPA05010020A (es) Derivados de oxamida.
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
WO2009069764A1 (ja) オピオイド鎮痛剤
EP1380299A4 (en) VESICAL STIMULATION MEDIUM IN CONNECTION WITH PROSTATE HYPERTROPHY
MX2009005250A (es) Compuestos 2-alquil-indazol para el tratamiento de ciertas enfermedades relacionadas con el sistema nervioso central (cns).

Legal Events

Date Code Title Description
FA Abandonment or withdrawal